Rapport Therapeutics Files S-1/A for IPO

TL;DR

Rapport Therapeutics is amending its IPO filing, getting closer to going public.

AI Summary

Rapport Therapeutics, Inc. filed an S-1/A amendment on June 3, 2024, for its initial public offering. The company, based in Boston, MA, is seeking to register an unspecified number of shares. This filing is an amendment to a previous registration statement, indicating ongoing preparations for its stock market debut.

Why It Matters

This S-1/A filing is a crucial step for Rapport Therapeutics as it moves closer to becoming a publicly traded company, which could impact its ability to fund future research and development.

Risk Assessment

Risk Level: medium — As a company in the pharmaceutical preparations sector undergoing an IPO, there are inherent risks associated with market reception and the company's ability to execute its business plan.

Key Numbers

• 02215 — ZIP Code (Principal business address in Boston, MA)
• 857-321-8020 — Phone Number (Principal executive offices phone number)

Key Players & Entities

• Rapport Therapeutics, Inc. (company) — Registrant
• Abraham N. Ceesay (person) — Chief Executive Officer
• Goodwin Procter LLP (company) — Legal Counsel
• 333-279486 (dollar_amount) — SEC File Number

FAQ

Key Financial Figures

• $16.00 — ffering price per share will be between $16.00 and $18.00. We have applied to list our
• $18.00 — ce per share will be between $16.00 and $18.00. We have applied to list our common sto
• $8 million — are expected to purchase approximately $8 million and $10 million, respectively, in share
• $10 m — o purchase approximately $8 million and $10 million, respectively, in shares of our c
• $17.00 — on the initial public offering price of $17.00 per share, which is the midpoint of the
• $2.8 b — d market for epilepsy was approximately $2.8 billion, and this is expected to grow to
• $3.6 billion — is is expected to grow to approximately $3.6 billion by 2028. There are an estimated 1.8 mil

Filing Documents

• d803738ds1a.htm (S-1/A) — 2592KB
• d803738dex11.htm (EX-1.1) — 206KB
• d803738dex31.htm (EX-3.1) — 129KB
• d803738dex32.htm (EX-3.2) — 29KB
• d803738dex34.htm (EX-3.4) — 119KB
• d803738dex51.htm (EX-5.1) — 5KB
• d803738dex102.htm (EX-10.2) — 213KB
• d803738dex103.htm (EX-10.3) — 44KB
• d803738dex104.htm (EX-10.4) — 150KB
• d803738dex105.htm (EX-10.5) — 13KB
• d803738dex106.htm (EX-10.6) — 12KB
• d803738dex107.htm (EX-10.7) — 64KB
• d803738dex108.htm (EX-10.8) — 62KB
• d803738dex109.htm (EX-10.9) — 62KB
• d803738dex231.htm (EX-23.1) — 2KB
• d803738dexfilingfees.htm (EX-FILING FEES) — 24KB
• g803738g00m02.jpg (GRAPHIC) — 40KB
• g803738g00m26.jpg (GRAPHIC) — 128KB
• g803738g00m27.jpg (GRAPHIC) — 134KB
• g803738g00m29.jpg (GRAPHIC) — 94KB
• g803738g00m30.jpg (GRAPHIC) — 108KB
• g803738g00m31.jpg (GRAPHIC) — 105KB
• g803738g00m33.jpg (GRAPHIC) — 112KB
• g803738g25c41.jpg (GRAPHIC) — 196KB
• g803738g35h11.jpg (GRAPHIC) — 141KB
• g803738g41i38.jpg (GRAPHIC) — 78KB
• g803738g56a01.jpg (GRAPHIC) — 80KB
• g803738g76c15.jpg (GRAPHIC) — 79KB
• g803738g91o98.jpg (GRAPHIC) — 122KB
• 0001193125-24-152294.txt ( ) — 5640KB

RISK FACTORS

RISK FACTORS 17 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 83

USE OF PROCEEDS

USE OF PROCEEDS 85 DIVIDEND POLICY 87 CAPITALIZATION 88

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 93

BUSINESS

BUSINESS 119 MANAGEMENT 167

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 178 DIRECTOR COMPENSATION 192 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 194 PRINCIPAL STOCKHOLDERS 198

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 202 SHARES ELIGIBLE FOR FUTURE SALE 208 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 210

UNDERWRITING

UNDERWRITING 215 LEGAL MATTERS 223 EXPERTS 223 WHERE YOU CAN FIND ADDITIONAL INFORMATION 223 INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS F-1 Through and including, 2024 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. We own

View Full Filing

View this S-1/A filing on SEC EDGAR